Tempus wants to be the operating system for cancer care. Co-founded by Eric Lefkofsky, the company plans to revolutionize not only how everyday patient data is used and stored, but also what types are being utilized. Tempus wants to do through this by making a person’s genetic information a regularly accessed part of their health care.
At a once extremely prohibitive cost over upwards of one hundred million dollars, the cost is predicted to drop to only a few hundred dollars in the foreseeable future. Currently standing at around five thousand, with the help of companies like Tempus, what once seemed straight out of science fiction could be reality. Care could be determined on a molecular level.
A patient’s genetic information is a potential key to find the best treatments available for a particular person’s case and type of cancer. This could also be utilized on a global scale to compare the information from patients and discover links to possible cures. Preventative medicine will also be a huge part of Tempus’ system. By knowing what someone is predisposed to, care can begin before the disease starts.
Tempus’ software is also designed to optically recognize hand-written notes and convert them into utilizable and searchable data. Eric Lefkofsky observed this was a problem when he noticed how much information was lost during his wife’s breast cancer treatments. Very important data was being lost as it was not being saved.
Eric Lefkofsky, a graduate of the University of Michigan with a Juris Doctor, has both success in business and his philanthropic endeavors. Members of the Giving Pledge and having recently donated millions to cancer initiatives, he and his wife are to donate half or more of their assets. Co-founded the Lefkofsky Foundation, the pair fund and assist initiatives that enhance the lives of those in and around the Chicago area. Lefkofsky acts as a trustee at the Lurie Children’s Hospital of Chicago as well as the Museum of Science and Industry.
For More info: www.lightbank.com/team/eric-lefkofsky
Dr. David Samadi is a board certified urologist at Lenox Hill Hospital in New York where he is chief of robotic surgery. He also serves as chairman of the urology department at Lenox Hill. Dr. David Samadi originally intended to be a cardiac surgeon but after observing a prostate surgery during his residency training, he became fascinated with the delicate procedures involving the gland. He also developed strategies inceasing the ability to extend the life of patients facing prostate cancer.
Dr. David Samadi is the host of a weekly show on LIVESTREAM called “Sunday House Call” that airs each Sunday at 12:30 EDT. He frequently invites guests, generally other physicians, who are top in their fields for question and answer call in sessions and interviews. This helps patients learn about various options in health care treatment or preventative measures that they can easily incorporate into their lives. Aspects such as diet, exercise and family history can be addressed as well as screenings for disease. They will discuss on what symptoms are particularly problematic and what are not unusual. While they cannot be a substitute for an actual exam, they can offer general recommendations and suggestions.
On Sunday, October 15, 2017, Dr. Samadi has secured Dr. CynaraCoomer on his show, which can be viewed live at Samaditv.com. Dr. Coomer is the Chief of Breast Surgery at Northwell Health Staten Island University Hospital. She also serves as the director of the Comprehensive Breast Health Center at that hospital.
Dr. Coomer will discuss the importance of breast health and will touch on different types of breast tumors. Dr. Samadi is pleased to host this show during Breast Cancer Awareness with one of the most esteemed doctors of breast health in the tri-state area, if not the entire country. They will welcome questions from viewers and offer tips on breast health.
Dr. David Samadi is very impressed with his former colleague’s extensive knowledge of breast health. Prior to her present position, Dr. Coomer was a breast surgeon at Mount Sinai Medical Center in New York, where she devoted her entire practice to treatment of breast diseases. Dr. Samadi is very impressed with Dr. Coomer’s extensive knowledge of breast health and is delighted to have her as a guest on his show. Dr. Coomer’s extensive knowledge of breast health will bring a special aspect of interest to Dr. Samadi’s live show on Sunday.
Read More: health.usnews.com/doctors/david-samadi-3908
Eric Lefkofsky is one of the most successful entrepreneurs that the country has ever seen. He already has three companies that have gone public, namely Echo Global Logistics, Groupon and InnerWorkings. After the success of his e-commerce company, he is interested in doing something in the health industry. He understood that there was a big gap between technology advancement and the health industry and wants to bring them both together to strengthen the industry. Even though big data has already been used in many different industries, its usage in the health industry is quite small. He wants to change this by developing Tempus. Tempus is a company that will compile genomic data to allow doctors to provide personalised treatment therapy depending on the condition of the patient.
Eric Lefkofsky was one of the founding members of the company and has been with the company since 2015. It was him who had the idea about the company and him along with other members brought it to life through Tempus. In a small amount of time the company has managed to draw the attention of the top most doctors and physicians as they feel it this big data company will allow them to find information quickly which is often important for them in treating their patients. They not only collect the data but have computer engineers who write algorithms to be able to analyze this data in an in-depth manner. Many health departments of institutions and hospitals have already formed a partnership with them, and they share their data with the company that can be used by them later on. Click here to know more.
Even though Mr. Eric is busy with his work commitment, he takes out time to indulge in charity events across the country. He and his wife started a family foundation in 2006 and had also signed the Giving Pledge. Over the years, their foundation has helped many different public and private organizations that are working towards the benefit of the community as a whole. Apart from that, he is also on the board of many different organizations like the Children’s Memorial in Chicago and the Art Institute of Chicago.
The current president and CEO of Seattle Genetics is Clay B. Siegall, Ph.D. He cofounded Seattle Genetics in 1998. He is an expert in science and biotechnology. He is talented and highly trained in the field of science and innovations. He is also a great entrepreneur. Dr. Siegall was named as the entrepreneur of the year in the region of Pacific Northwest back in 2012. He has been in leadership for many years and hence, he has great and admirable experience. His leadership techniques are spectacular because of his excellent knowledge and ability to work with a team of experts.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Education background and experience of Dr. Siegall
Dr. Clay Siegall is a Doctor of Philosophy which was a great achievement at George Washington University in the USA. Siegall holds a bachelor’s degree in Science (Zoology) from the University of Maryland. He is a great leader and an individual with a great passion for science and innovation. His skills have enabled him to achieve more his roles of leadership. It is proved by the many organizations that he leads. He is also a director in many companies which include Ultragenix Pharmaceutical, Mirna Therapeutics, and Alder Biopharmaceuticals.
The foundation of Seattle Genetics
It was established back in 1998 under the leadership of Dr. Clay Siegall. He was driven by the passion for helping the patients who are needy in the opening of the company. The company was built on great scientific innovations and thorough research. The company has achieved more under the supervision of Dr. Clay Siegall. One of the biggest achievements of the company is the invention of the (ADCs) antibody drugs conjugates. The drugs were approved in a ceremonial event by the US government in the administration of medications and food back in 2011. The drugs gained popular recognition countrywide.
Dr. Siegall has led the company to the achievement of many other things. It is now a stable company in the field of biotechnology. The company serves a large number of patients from the US and other foreigners. It has won several honorary awards has invested in many areas. The company has an excellent vision and objectives of becoming a global leader in cancer treatment and biotechnology.